SHARP Diagnostics develops affordable, rapid, and accurate nucleic acid detection technology using isothermal amplification. This technology simplifies diagnostics, making essential medical testing accessible in all settings and improving early disease detection, treatment, and global health equity.
FELLOW
Momcilo Gavrilov
Momcilo Gavrilov is CEO of SHARP Diagnostics, a biotechnology company developing rapid, portable, and affordable DNA amplification technologies. Gavrilov combines cutting-edge science, strategic partnerships, and top-tier talent to commercialize breakthrough innovations. He holds a B.Sc. in applied physics (University of Belgrade) and a Ph.D. in physics (Simon Fraser University) with a focus on thermodynamics of information. He completed a biophysics postdoc at Johns Hopkins University studying motor proteins. Previously, he developed diagnostics and sensing technologies at Honeywell International.
TECHNOLOGY
Critical Need
SHARP Diagnostics addresses the urgent need for rapid, accurate, and affordable nucleic acid detection in biotechnology and medicine. Existing diagnostic methods are often slow and costly and require complex equipment and trained personnel. SHARP Diagnostics' platform simplifies this process, offering quicker and more cost-effective diagnostics crucial for early disease detection, genetic condition monitoring, and infectious disease management.
Technology Vision
SHARP Diagnostics' platform uses isothermal amplification to detect nucleic acids, eliminating the need for complex thermal cycling equipment. This technology operates at a constant temperature, enabling faster, more accurate, and cost-effective diagnostics. Its portable, user-friendly design allows widespread use, even in resource-limited areas, enhancing early disease detection and improving accessibility to essential medical testing.
Potential for Impact
When scaled, SHARP Diagnostics' innovation will revolutionize healthcare by making rapid, accurate, and affordable diagnostic testing accessible globally. This will enable earlier disease detection, timely treatments, and better management of genetic conditions and infectious diseases. Widespread adoption will reduce healthcare costs, improve patient outcomes, and enhance global health equity by providing critical diagnostic tools to all, regardless of location or resources.
Website
SHARP Diagnostics